PE20021035A1 - Composiciones que contienen imidazotriazinona para administracion nasal - Google Patents
Composiciones que contienen imidazotriazinona para administracion nasalInfo
- Publication number
- PE20021035A1 PE20021035A1 PE2002000303A PE2002000303A PE20021035A1 PE 20021035 A1 PE20021035 A1 PE 20021035A1 PE 2002000303 A PE2002000303 A PE 2002000303A PE 2002000303 A PE2002000303 A PE 2002000303A PE 20021035 A1 PE20021035 A1 PE 20021035A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- local anesthetic
- formula
- halogen
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical compound O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- -1 PIPERIDINYL Chemical class 0.000 abstract 3
- 239000003589 local anesthetic agent Substances 0.000 abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 abstract 1
- 229920001363 Polidocanol Polymers 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229960005274 benzocaine Drugs 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 229960000400 butamben Drugs 0.000 abstract 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 abstract 1
- 229960002023 chloroprocaine Drugs 0.000 abstract 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 229960004194 lidocaine Drugs 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003502 oxybuprocaine Drugs 0.000 abstract 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 229960001045 piperocaine Drugs 0.000 abstract 1
- 229960002226 polidocanol Drugs 0.000 abstract 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 229960004919 procaine Drugs 0.000 abstract 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 229960002372 tetracaine Drugs 0.000 abstract 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION NASAL QUE COMPRENDE i)UN INHIBIDOR DE FOSFODIESTERASA DE 3',5'-MONOFOSFATO DE GUANOSIN CICLICA PDE GMPc, TAL COMO IMIDAZOTRIAZINONAS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C4; R2 ES ALQUILO C1-C4; R3 Y R4 SON ALQUILO C1-C5 OPCIONALMENTE SUSTITUIDo CON HIDROXI, METOXI O JUNTO A N FORMAN PIPERIDINILO, MORFOLINILO, TIOMORFOLINILO, PIPERAZINA SUSTITUIDO CON R7; R7 ES H, FORMILO, ACILO, ALCOXICARBONILO, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C6, OH, ALCOXI C1-C6; SON COMPUESTOS PREFERIDOS 2-[2-ETOXI-5-[(4-ETILPIPERAZIN-1-IL)SULFONIL]FENIL]-5-METIL-7-PROPIL-IMIDAZO[5,1-f][1,2,4]TRIAZIN-4(3H)-ONA; UTILIZANDO DE 0,5g/Kg A 200 g/Kg; ii)UN ANESTESICO LOCAL TAL COMO a)UN COMPUESTO DE FORMULA II, R1 ES H, NH2, NH(ALQUILO C1-C6), O-ALQUILO C1-C6, CH2OPh; R2 ES (CH2)(1-6)-HET, O-ALQUILO C1-C6; R3 ES H, HALOGENO, ALQUILO C1-C6; b)UN COMPUESTO DE FORMULA III, R1 ES H, OH; R2 ES ALQUIL C1-C6-N-(ALQUILO C1-C6)2; R3 ES ALQUILO C1-C6, HALOGENO, COO-ALQUILO C1-C6; ENTRE OTROS; n ES 1-2; c)LIDOCAINA, BENZOCAINA, TETRACAINA, BENOXINATO, POLIDOCANOL, BUTAMBEN, PIPEROCAINA, PROCAINA, CLOROPROCAINA, ENTRE OTROS, UTILIZANDO UNA CONCENTRACION MENOR DEL 4%; CON LA CONDICION QUE EL ANESTESICO LOCAL NO ES ALCOHOL BENCILICO; iii)DISOLVENTE O COADYUVANTES COMO TAMPONES, SUSTANCIAS POTENCIADORAS DE VISCOSIDAD, CONSERVANTES, ENTRE OTROS. LA COMPOSICION AL CONTENER EL ANESTESICO LOCAL EVITA EL ESTADO DE SENSACION DESAGRADABLE, LAGRIMAS, AUMENTO DE LA RESISTENCIA RESPIRATORIA NASAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10118306A DE10118306A1 (de) | 2001-04-12 | 2001-04-12 | Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021035A1 true PE20021035A1 (es) | 2002-11-29 |
Family
ID=7681379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000303A PE20021035A1 (es) | 2001-04-12 | 2002-04-11 | Composiciones que contienen imidazotriazinona para administracion nasal |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6740306B2 (es) |
| EP (1) | EP1381368A2 (es) |
| JP (1) | JP2004525968A (es) |
| KR (1) | KR20030087072A (es) |
| CN (1) | CN1537004A (es) |
| AR (1) | AR035821A1 (es) |
| BG (1) | BG108245A (es) |
| BR (1) | BR0208813A (es) |
| CA (1) | CA2443639A1 (es) |
| CZ (1) | CZ20032752A3 (es) |
| DE (1) | DE10118306A1 (es) |
| DO (1) | DOP2002000373A (es) |
| EC (1) | ECSP034795A (es) |
| EE (1) | EE200300501A (es) |
| GT (1) | GT200200070A (es) |
| HU (1) | HUP0303877A3 (es) |
| IL (1) | IL158255A0 (es) |
| MX (1) | MXPA03009314A (es) |
| NO (1) | NO20034556L (es) |
| PE (1) | PE20021035A1 (es) |
| PL (1) | PL363033A1 (es) |
| RU (1) | RU2003133143A (es) |
| SK (1) | SK12682003A3 (es) |
| UY (1) | UY27256A1 (es) |
| WO (1) | WO2002083674A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03010119A (es) * | 2001-05-09 | 2005-03-07 | Bayer Healthcare Ag | Nuevo uso de imidazotriazinonas 2-fenilo sustituidas. |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| CA2587792C (en) * | 2004-12-23 | 2010-07-06 | Roxro Pharma, Inc. | Therapeutic compositions for intranasal administration of ketorolac |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
| DE102005009240A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| WO2007002125A1 (en) * | 2005-06-23 | 2007-01-04 | Schering Corporation | Rapidly absorbing oral formulations of pde5 inhibitors |
| SG166106A1 (en) * | 2005-09-29 | 2010-11-29 | Bayer Schering Pharma Ag | Pde inhibitors and combinations thereof for the treatment of urological disorders |
| KR20100029762A (ko) * | 2007-06-13 | 2010-03-17 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 청력 장애 치료용 ｐｄｅ 억제제 |
| MX2010013484A (es) * | 2008-06-13 | 2011-03-29 | Roxro Pharma Inc Star | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. |
| US8551454B2 (en) * | 2009-03-13 | 2013-10-08 | Luitpold Pharmaceuticals, Inc. | Device for intranasal administration |
| US8277781B2 (en) * | 2009-03-13 | 2012-10-02 | Luitpold Pharmaceuticals, Inc. | Device for intranasal administration |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| WO2020006606A1 (en) * | 2018-07-05 | 2020-01-09 | Helium 3 Resources Pty Ltd | A pharmaceutical composition and method of use of same |
| SE542968C2 (en) * | 2018-10-26 | 2020-09-22 | Lindahl Anders | Treatment of osteoarthritis |
| WO2021242913A1 (en) * | 2020-05-26 | 2021-12-02 | Strategic Drug Solutions, Inc. | Formulations and methods for treating erectile dysfunction |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4602099A (en) * | 1973-04-02 | 1986-07-22 | Merrell Dow Pharmaceuticals Inc. | Antirhinovirus agents |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| US6018046A (en) | 1996-05-31 | 2000-01-25 | Mochida Pharmaceutical Co., Ltd. | Pyridocarbazole derivatives having cGMP-PDE inhibitory activity |
| GB2315673A (en) * | 1996-08-01 | 1998-02-11 | Merck & Co Inc | Treatment of migraine |
| WO1998053819A1 (en) * | 1997-05-29 | 1998-12-03 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for erection failure |
| WO1999015177A1 (en) | 1997-09-23 | 1999-04-01 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| CA2309332C (en) | 1997-11-12 | 2002-12-03 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| TWI223598B (en) * | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| WO2000000199A1 (en) * | 1998-06-26 | 2000-01-06 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of sildenafil citrate |
| AU764921B2 (en) * | 1998-12-14 | 2003-09-04 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
-
2001
- 2001-04-12 DE DE10118306A patent/DE10118306A1/de not_active Withdrawn
-
2002
- 2002-04-03 HU HU0303877A patent/HUP0303877A3/hu unknown
- 2002-04-03 WO PCT/EP2002/003663 patent/WO2002083674A2/de not_active Ceased
- 2002-04-03 PL PL02363033A patent/PL363033A1/xx not_active Application Discontinuation
- 2002-04-03 BR BR0208813-4A patent/BR0208813A/pt not_active Application Discontinuation
- 2002-04-03 KR KR10-2003-7013280A patent/KR20030087072A/ko not_active Withdrawn
- 2002-04-03 JP JP2002581429A patent/JP2004525968A/ja active Pending
- 2002-04-03 RU RU2003133143/15A patent/RU2003133143A/ru not_active Application Discontinuation
- 2002-04-03 EP EP02732548A patent/EP1381368A2/de not_active Withdrawn
- 2002-04-03 CA CA002443639A patent/CA2443639A1/en not_active Abandoned
- 2002-04-03 CN CNA028114574A patent/CN1537004A/zh active Pending
- 2002-04-03 IL IL15825502A patent/IL158255A0/xx unknown
- 2002-04-03 SK SK1268-2003A patent/SK12682003A3/sk unknown
- 2002-04-03 CZ CZ20032752A patent/CZ20032752A3/cs unknown
- 2002-04-03 EE EEP200300501A patent/EE200300501A/xx unknown
- 2002-04-03 MX MXPA03009314A patent/MXPA03009314A/es unknown
- 2002-04-04 DO DO2002000373A patent/DOP2002000373A/es unknown
- 2002-04-10 AR ARP020101322A patent/AR035821A1/es not_active Application Discontinuation
- 2002-04-11 US US10/122,694 patent/US6740306B2/en not_active Expired - Fee Related
- 2002-04-11 PE PE2002000303A patent/PE20021035A1/es not_active Application Discontinuation
- 2002-04-11 GT GT200200070A patent/GT200200070A/es unknown
- 2002-04-11 UY UY27256A patent/UY27256A1/es not_active Application Discontinuation
-
2003
- 2003-10-08 EC EC2003004795A patent/ECSP034795A/es unknown
- 2003-10-09 BG BG108245A patent/BG108245A/xx unknown
- 2003-10-10 NO NO20034556A patent/NO20034556L/no not_active Application Discontinuation
-
2004
- 2004-03-30 US US10/813,801 patent/US20040248891A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20032752A3 (cs) | 2004-01-14 |
| DE10118306A1 (de) | 2002-10-17 |
| NO20034556D0 (no) | 2003-10-10 |
| ECSP034795A (es) | 2003-12-01 |
| BG108245A (en) | 2005-01-31 |
| US20040248891A1 (en) | 2004-12-09 |
| JP2004525968A (ja) | 2004-08-26 |
| WO2002083674A3 (de) | 2003-01-09 |
| CN1537004A (zh) | 2004-10-13 |
| EE200300501A (et) | 2003-12-15 |
| IL158255A0 (en) | 2004-05-12 |
| GT200200070A (es) | 2003-01-31 |
| SK12682003A3 (sk) | 2004-03-02 |
| AR035821A1 (es) | 2004-07-14 |
| PL363033A1 (en) | 2004-11-15 |
| UY27256A1 (es) | 2002-11-29 |
| DOP2002000373A (es) | 2002-11-30 |
| KR20030087072A (ko) | 2003-11-12 |
| NO20034556L (no) | 2003-12-10 |
| EP1381368A2 (de) | 2004-01-21 |
| CA2443639A1 (en) | 2002-10-24 |
| HUP0303877A2 (hu) | 2004-03-29 |
| HUP0303877A3 (en) | 2005-05-30 |
| WO2002083674A2 (de) | 2002-10-24 |
| BR0208813A (pt) | 2004-03-09 |
| MXPA03009314A (es) | 2004-03-10 |
| US6740306B2 (en) | 2004-05-25 |
| RU2003133143A (ru) | 2005-04-10 |
| US20030022894A1 (en) | 2003-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021035A1 (es) | Composiciones que contienen imidazotriazinona para administracion nasal | |
| EA200401056A1 (ru) | Комбинация, содержащая производные тропана, полезные в терапии | |
| ATE450260T1 (de) | Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden | |
| ECSP024364A (es) | Antagonistas receptores de adenosina a2a | |
| PA8610801A1 (es) | Compuestos de aril o heteroaril amida | |
| ES2175480T3 (es) | Composiciones limpiadoras y desinfectantes mejoradas, de tipo eflorescente. | |
| PE20090733A1 (es) | Derivados de pirazina como bloqueadores de los canales de sodio epitelial | |
| DK1646389T3 (da) | Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister | |
| PE20081493A1 (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso | |
| PE23196A1 (es) | Compuesto util para tratar infecciones por retrovirus | |
| AP2001002307A0 (en) | B3 adrenergic receptor agonists and uses thereof. | |
| PE20081579A1 (es) | Derivados de benzamida como agonistas del receptor | |
| AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR013454A1 (es) | Metodo para el tratamiento de las enfermedades pulmonares con 5'-difosfato de uridina y analogos del mismo, composiciones formuladas con dichos compuestosy los compuestos mencionados. | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| BR9704937A (pt) | Derivados de diamino-1,3,5-triazina substituìda | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| AR076362A1 (es) | Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras. | |
| UY29169A1 (es) | Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica | |
| ATE273277T1 (de) | Piperidinyl- und n-amidinopiperidinyl-derivate | |
| AR018619A1 (es) | Derivados de 8-fenilxantina utiles como inhibidores de fosfoestearasa gmp ciclica (pdes), preparacion, composiciones farmaceuticas formuladas con dichosderivados y uso de dichos derivados para la fabricacion de medicamentos | |
| PE20241726A1 (es) | Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits | |
| BRPI0412118A (pt) | métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes | |
| AR022797A1 (es) | Benzoil indoles n-sustituidos como agentes estrogenicos | |
| CY1110572T1 (el) | Στοματικο αντικαταθλιπτικο σκευασμα το οποιο περιλαμβανει ακετυλοσαλικυλικο οξυ για επιταχυνση της εναρξης δρασης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |